Adynxx (ADYX) 10-Q 4 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 31, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		29,672,025

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 10,701	$ 26,080
Accounts receivable, net	2,705	2,060
Inventory, net	3,226	2,275
Prepaid expenses and other current assets	890	942
Current assets of discontinued operations	28	1,315
Total current assets	17,550	32,672
Improvements and equipment, net	2,211	1,847
Intangible assets, net	31,056	33,667
Goodwill	21,166	21,166
Other assets	173	173
Note receivable	503	0
Assets of discontinued operations - noncurrent	0	227
Total assets	72,659	89,752
Current Liabilities:
Accounts payable	2,590	2,594
Accrued expenses and other current liabilities	3,947	3,071
Contingent consideration, current	1,399	2,573
Long-term debt, net	11,336	0
Warrant liability	64	861
Current liabilities of discontinued operations	0	103
Total current liabilities	19,336	9,202
Long-term debt, net	0	12,126
Contingent consideration, long-term	1,848	14,455
Deferred tax liability	1,477	1,468
Other long-term liabilities	1,359	76
Total liabilities	24,020	37,327
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 29,672,025 and 27,668,913 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively	30	28
Additional paid-in capital	155,767	148,457
Accumulated deficit	(107,158)	(96,060)
Total stockholders’ equity	48,639	52,425
Total liabilities and stockholders’ equity	$ 72,659	$ 89,752

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	29,672,025	27,668,913
Common stock, shares outstanding	29,672,025	27,668,913

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue, net of returns, allowances and discounts	$ 4,874	$ 4,185	$ 13,298	$ 8,234
Cost of revenues	1,766	1,436	4,955	3,658
Gross profit	3,108	2,749	8,343	4,576
Operating expenses
Selling, general and administrative	8,902	10,151	28,307	24,661
Research and product development	164	192	692	493
Milestone expense to licensor	1,000	0	1,000	0
Acquisition-related	715	15	819	2,875
Change in fair value of contingent consideration liability	97	585	(8,634)	957
Total operating expenses	10,878	10,943	22,184	28,986
Loss from operations	(7,770)	(8,194)	(13,841)	(24,410)
Other (expense) income
Interest expense	(686)	(667)	(1,957)	(900)
Interest income	9	13	24	31
Change in fair value of warrant liability	135	1,466	797	1,388
Loss on early extinguishment of debt	(373)	0	(373)	0
Other income	100	0	100	0
Total other (expense) income	(815)	812	(1,409)	519
Loss from continuing operations before tax	(8,585)	(7,382)	(15,250)	(23,891)
Income tax (expense) benefit	(3)	(129)	(9)	1,308
Loss from continuing operations	(8,588)	(7,511)	(15,259)	(22,583)
Discontinued operations:
Income from discontinued operations, net of tax of $0 for the three and nine months ended September 30, 2016 and 2015	0	379	850	799
Gain on sale of assets, net of tax of $0 for the three and nine months ended September 30, 2016 and 2015	0	0	3,311	0
Income from discontinued operations, net of tax	0	379	4,161	799
Net loss	$ (8,588)	$ (7,132)	$ (11,098)	$ (21,784)
Net loss per basic and diluted common share:
Loss from continuing operations	$ (0.3)	$ (0.27)	$ (0.55)	$ (1.04)
Income from discontinued operations	0	0.01	0.03	0.04
Gain on sale of assets	0	0	0.12	0
Total from discontinued operations	0	0.01	0.15	0.04
Weighted average shares used in computing net income (loss) per common share:
Net loss per basic and diluted common share	$ (0.30)	$ (0.26)	$ (0.40)	$ (1)
Weighted average shares used in computing basic and diluted net loss per common share	28,195,674	26,930,880	27,886,959	21,742,504

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period	$ 0	$ 0	$ 0	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating Activities
Net loss	$ (11,098)	$ (21,784)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,124	1,848
Amortization of deferred lease incentive	(23)	(6)
Deferred income tax expense (benefit)	9	(1,308)
Provision for doubtful accounts	37	66
Provision for excess and slow moving inventory	(54)	12
Stock-based compensation expense	4,268	6,580
Deferred rent	84	0
Accrued interest receivable	(3)	0
Amortization of debt issuance and debt discount costs	636	326
Loss on early extinguishment of debt	373	0
Change in fair value of warrant liability	(797)	(1,388)
Fair value adjustment of contingent consideration liability	(8,634)	957
Gain on sale of assets	(3,311)	0
Changes in operating assets and liabilities:
Accounts receivable	(254)	(610)
Inventory	(643)	(1,738)
Prepaid expenses and other assets	55	(250)
Accounts payable	(48)	777
Accrued expenses and other current liabilities	1,297	(645)
Other long-term liabilities	1,000	0
Net Cash Used in Operating Activities	(14,034)	(17,162)
Investing Activities
Proceeds from sale of assets	4,103	0
Purchase of improvements and equipment	(573)	(231)
Acquisition of business, net of cash acquired	0	(14,948)
Issuance of bridge loan	(500)	0
Net Cash Provided by (Used in) Investing Activities	3,030	(15,179)
Financing Activities
Contingent purchase price payments	(2,573)	0
Repayment of long-term debt	(1,748)	0
Loss on early extinguishment of debt	(52)	0
Net proceeds from issuance of common stock	0	32,197
Net proceeds from long-term debt	0	14,244
Proceeds from the exercise of stock options	0	332
Payment of withholding taxes related to stock-based employee compensation	(2)	(471)
Net Cash (Used in) Provided by Financing Activities	(4,375)	46,302
Net (Decrease) Increase in Cash and Cash Equivalents	(15,379)	13,961
Cash and Cash Equivalents - Beginning of period	26,080	16,771
Cash and Cash Equivalents - End of period	10,701	30,732
Supplemental Disclosure of Cash Flows Information
Interest	1,221	435
Non-cash investing and financing activities:
Extinguishment of warrant liability due to cashless warrant exercise	0	31
2015 Accrued bonus awarded in equity	474	0
Common stock issued for contingent purchase price payments	2,574	0
Acquisition of business:
Current assets, excluding cash and cash equivalents	0	1,836
Intangibles	0	31,952
Goodwill	0	16,825
Liabilities assumed	0	(2,006)
Deferred tax liability	0	(2,881)
Contingent consideration	0	(15,570)
Issuance of common stock for acquisition	$ 0	$ (15,208)

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (the “Company”) is a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue. The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2016 and results of operations and cash flows for the three and nine months ended September 30, 2016. The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation. Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported. The Company’s significant accounting policies are disclosed in Note 2 – Summary of Significant Accounting Policies In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” ASU No. 2016-15 clarifies and provides specific guidance on eight cash flow classification issues that are not currently addressed by current GAAP and thereby reduce the current diversity in practice. ASU No. 2016-15 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017, with early application permitted. This guidance is applicable to the Company's fiscal year beginning January 1, 2018. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, which for the Company will commence with the year beginning January 1, 2018, with early adoption permitted commencing January 1, 2017. The Company is currently evaluating the standard to determine the impact of its adoption on the condensed consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. The standard is effective for annual reporting periods beginning after December 15, 2018, which for the Company will commence with the year beginning January 1, 2019, with early application permitted. The adoption will require a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest period presented. The Company is currently evaluating the standard to determine the impact of the adoption on the consolidated financial statements. In May 2014, the FASB issued a new revenue recognition standard entitled “Revenue from Contracts with Customers” under Accounting Standards Update 2014-09. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB approved a one-year delay to the required adoption date of the standard, which makes it effective for the Company no later than the first quarter of 2018, with adoption in 2017 permitted. In 2016, the FASB issued amendments to clarify the implementation guidance related to principal versus agent considerations, identifying performance obligations and the accounting for licenses of intellectual property. The new standard is required to be applied retrospectively to each prior reporting period or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application. The Company has not yet selected a transition method and is currently evaluating the standard to determine the impact of adoption on the Company’s consolidated financial statements.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	2. Going Concern The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. As of September 30, 2016, the Company had a cash balance of $ 10.7 11.1 14.0 107.2 22,250 13.8 52 On October 5, 2016, the Company signed a definitive agreement to acquire the business of Soluble Systems, LLC (“Soluble”) through a series of transactions. The closing of the transactions are conditioned upon, among other things, the Company securing debt or equity financing, or combination, thereof, that results in gross proceeds of at least $ 45 26.2 Management is evaluating all options to raise sufficient funds to meet the financing contingency of the Soluble transaction, to refinance its outstanding indebtedness and to fund the Company’s working capital requirements through debt and/or equity offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company. There is no assurance that the Company will be successful in achieving profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Net Loss Per Common Share Basic income (loss) per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted income (loss) per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock. As of September 30, 2016 2015 Stock options 7,338,621 6,300,359 Warrants 3,365,407 3,372,550 Non-vested restricted stock 1,473,217 737,902 Total 12,177,245 10,410,811

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Acquisitions Acquisition of Celleration, Inc. On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds for an aggregate purchase price of approximately $ 46.3 15.5 0.3 3,168,229 15.6 The Company has agreed to pay contingent consideration of 3.5 The first installment consisted of $ 2.6 986,000 2.6 10.2 8.7 As of September 30, 2016, the Company has recorded a liability of approximately $ 2.8 81,000 8.5 406,000 At the date of acquisition and September 30, 2016, the cash flow projection was discounted using a weighted average cost of capital of 12.5 These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. Pro Forma Results The following unaudited pro forma financial information summarizes the results of operations for the nine months ended September 30, 2015, as if the acquisition had been completed as of January 1, 2015. The pro forma results were calculated applying the Company’s accounting policies and include the effects of adjustments related to the amortization charges from the acquired intangibles and long-term debt. The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future. Nine Months Ended Revenues $ 12,324 Net loss $ (27,382) Net loss per share $ (1.17)

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	5. Discontinued Operations Asset Sale In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective June 30, 2016, the Company entered into a purchase agreement (the “Purchase Agreement”) with BSN medical, Inc. (“BSN”) whereby the Company agreed to sell to BSN (i) all of the Company’s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights (collectively, the “Rights”) to the sorbion product line pursuant to its distribution agreement (as amended, the “Sorbion Agreement”) with Sorbion GmbH & Co KG and (ii) the unsold inventory of sorbion products previously purchased by the Company) in existence as of the closing, which occurred upon execution and delivery of the Purchase Agreement. In consideration for the sale of the Rights and the unsold sorbion inventory to BSN by the Company, BSN agreed to pay (i) $ 3.5 900,000 3.3 0 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311 On June 30, 2016, the Company entered into a ninety-day transition services agreement with BSN (“Transition Agreement”). Under the Transition Agreement, the Company was required to perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the business to BSN, as specified in the Transition Agreement. As compensation, BSN paid the Company $ 100,000 Discontinued Operations Three Months Ended Ended September 30, Nine Months Ended Ended September 30, 2015 2016 2015 Revenue, net of returns, allowances and discounts $ 828 $ 1,709 $ 2,029 Cost of revenues 225 536 583 Gross profit 603 1,173 1,446 Selling, general and administrative 224 323 647 Income from discontinued operations, net of tax $ 379 $ 850 $ 799 Non-cash amortization expense of $ 19,000 38,000 57,000 September 30, December 31, 2016 2015 Accounts receivable, net $ 28 $ 457 Inventory, net - 858 Total current assets 28 1,315 Intangible assets, net - 227 Total assets 28 1,542 Accounts payable - 44 Accrued expenses and other current liabilities - 59 Total current liabilities $ - $ 103

Note Receivable

Note Receivable	9 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Financing Receivables [Text Block]	6. Note Receivable On August 25, 2016 in connection with the definitive agreement to acquire the business of Soluble, the Company provided Soluble with a $ 500,000 6 3,000

Inventory

Inventory	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Inventory September 30, December 31, 2016 2015 Raw materials $ 162 $ 241 Work in process 296 228 Finished goods 2,773 1,865 Less: Inventory reserve for excess and slow moving inventory (5) (59) Total $ 3,226 $ 2,275

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Accrued Expenses September 30, December 31, 2016 2015 Salaries, benefits and incentive compensation $ 2,326 $ 2,118 Professional fees 726 671 Royalty fees 570 52 Deferred revenue 142 92 Other 183 138 Total accrued expenses and other current liabilities $ 3,947 $ 3,071

Debt

Debt	9 Months Ended
	Sep. 30, 2016
Debt Instruments [Abstract]
Long-term Debt [Text Block]	9. Debt Senior Secured Term Loan Facility On May 29, 2015, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $ 15.5 accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75% is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000, which was amended in conjunction with the extinguishment of debt described below from the greater of 1% of the outstanding principal balance immediately prior to the final payment or $100,000. The interest rate at September 30, 2016 was 10.75 In connection with the Credit Agreement, the Company incurred approximately $ 1.3 64,000 209,000 72,000 98,000 In connection with the entry into the Credit Agreement, a five-year warrant 750,000 0.001 5.5138 2.7 143,000 427,000 168,000 227,000 – Fair Value Measurement As of September 30, 2016, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement as a result of the Company’s failure to achieve gross revenue of $ 22,250 13.8 as a current liability in its balance sheet as of September 30, 2016 . Extinguishments On June 30, 2016, the Company entered into a Consent Under Credit Agreement (the “Consent Agreement”) with Perceptive pursuant to which Perceptive consented to the Purchase Agreement with BSN (see Note 5 – Discontinued Operations 1,800,000 1.7 52,000 373,000 52,000 226,000 95,000 September 30, December 31, 2016 2015 Long-term debt $ 13,752 $ 15,500 Unamortized debt issuance and discount costs (2,416) (3,374) Total $ 11,336 $ 12,126

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies License Agreement On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75 600,000 150,000 125,000 450,000 375,000 449,000 497,000 Agreements for Human Placental Based Products Human Longevity, Inc. In January 2016, Human Longevity, Inc.’s (“HLI”), a genomics-based, technology-driven company, announced the purchase of LifebankUSA and other select assets from Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”). CCT assigned and HLI assumed the license and supply agreements the Company entered into with CCT for certain placental based products. In April 2016, the Company entered into a Supply Agreement with HLI, pursuant to which HLI supplies the Company with the Company’s entire requirement of Interfyl™ Human Connective Tissue Matrix (CTM). Additionally, the Company agreed to make certain future milestone payments upon the achievement of certain milestones. The Company initiated sales and marketing efforts of Interfyl™ Human Connective Tissue Matrix in September 2016 and achieved two of three milestones under the license agreement. The Company is required to pay HLI $ 500,000 500,000 1,000,000 Operating Lease 27,000 78,000 80,000 82,000 84,000 577,000 Litigation, Claims and Assessments The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of September 30, 2016.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2016
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Stockholders’ Equity Common Stock On May 6, 2016, the Company held its 2016 annual meeting of stockholders. The stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 45,714,286 95,000,000 Stock-Based Compensation During the three and nine months ended September 30, 2016, the Company recognized $ 1.2 4.3 5,000 134,000 1.2 4.1 2.3 6.6 91,000 273,000 2.2 6.3 4.7 1.3 Restricted Stock On February 9, 2016, the Company granted 324,561 474,000 On May 11, 2016, the Company granted 700,000 602,000 Stock Options Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Risk free interest rate 1.15%-1.44 % 0.32%-2.07 % 0.46%-2.06 % 0.26%-2.11 % Expected term (years) 5.50-6.50 0.76-6.50 0.53-6.50 0.76-6.50 Expected volatility 89.95 % 93.70 % 89.95 % 97.37 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the "simplified method" to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future. Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2015 6,230,549 $ 6.26 - $ - Granted 1,639,000 1.05 Exercised - - Forfeited (530,928) 3.83 Outstanding, September 30, 2016 7,338,621 $ 5.28 7.3 $ - Exerciseable, September 30, 2016 4,146,376 $ 6.14 6.4 $ - The weighted average estimated fair value per share of the options granted during the three and nine months ended September 30, 2016 was $ 0.76 0.76 The weighted average estimated fair value per share of the options granted during the three and nine months ended September 30, 2015 was $ 3.78 4.27

Related Party

Related Party	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Related Party In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director is a member of the Board of Directors. During the three and nine months ended September 30, 2016, the Company incurred costs of approximately $ 100,000 358,000 30,000 5,000

Concentration of Risk

Concentration of Risk	9 Months Ended
	Sep. 30, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	13. Concentration of Risk % of Total Revenue Accounts Receivable Customer 2016 2015 September 30, 2016 A 9 % 11 % 3 %

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	14. Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. On September 30, 2016, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 816,287 64,000 66.95 69.55 0.59 1.01 1.11 3.66 0.00 135,000 797,000 1.5 1.4 Acquisitions Nine Months Ended September 30, 2016 2015 Warrant Liabilities Beginning balance $ 861 $ 304 Change in fair value of warrant liability (797) (1,388) Value of warrants issued - 2,683 Value of warrants exercised - (31) Ending balance $ 64 $ 1,568 Nine Months Ended September 30, 2016 2015 Contingent Consideration Beginning balance $ 17,028 $ 2,932 Initial fair value of contingent consideration - 15,570 Payments of contingent consideration (5,147) - Change in fair value of contingent consideration (8,634) 957 Ending balance $ 3,247 $ 19,459 September 30, 2016 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 64 Contingent consideration - - 3,247 Total liabilities $ - $ - $ 3,311 December 31, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 861 Contingent consideration - - 17,028 Total liabilities $ - $ - $ 17,889 Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes The difference between the statutory income tax rate and the effective income tax rate is that the Company anticipates having a tax loss for the full fiscal 2016 year. During the nine months ended September 30, 2015, the Company recorded an income tax benefit of approximately $ 1.3 1.4

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16. Subsequent Events On October 5, 2016, the Company entered into a Contribution Agreement and Plan of Merger (the “Contribution and Merger Agreement”) with Alliqua Holdings, Inc., a wholly owned subsidiary of the Company (“New Alliqua”), Chesapeake Merger Corp., a wholly owned subsidiary of New Alliqua (“Merger Sub”), and Soluble Systems, LLC (“Soluble”), pursuant to which, among other things, the Company will reorganize into a new holding company by merging Merger Sub with and into the Company, with the Company surviving as a wholly owned subsidiary of New Alliqua. In addition, following the effective time of the merger, Soluble will contribute substantially all of its assets to New Alliqua, and New Alliqua will assume or payoff certain liabilities of Soluble, in exchange for certain consideration. The closing of the transactions are conditioned upon, among other things, the Company securing debt or equity financing, or combination, thereof, that results in gross proceeds of at least $ 45 26.2 Note Receivable 500,000 1,000,000 500,000

Description of Business and B23

Description of Business and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of September 30, 2016 and results of operations and cash flows for the three and nine months ended September 30, 2016.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Significant Accounting Policies and Estimates [Policy Text Block]	Significant Accounting Policies and Estimates The Company’s significant accounting policies are disclosed in Note 2 – Summary of Significant Accounting Policies
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” ASU No. 2016-15 clarifies and provides specific guidance on eight cash flow classification issues that are not currently addressed by current GAAP and thereby reduce the current diversity in practice. ASU No. 2016-15 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017, with early application permitted. This guidance is applicable to the Company's fiscal year beginning January 1, 2018. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, which for the Company will commence with the year beginning January 1, 2018, with early adoption permitted commencing January 1, 2017. The Company is currently evaluating the standard to determine the impact of its adoption on the condensed consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. The standard is effective for annual reporting periods beginning after December 15, 2018, which for the Company will commence with the year beginning January 1, 2019, with early application permitted. The adoption will require a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest period presented. The Company is currently evaluating the standard to determine the impact of the adoption on the consolidated financial statements. In May 2014, the FASB issued a new revenue recognition standard entitled “Revenue from Contracts with Customers” under Accounting Standards Update 2014-09. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. New disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers are also required. In August 2015, the FASB approved a one-year delay to the required adoption date of the standard, which makes it effective for the Company no later than the first quarter of 2018, with adoption in 2017 permitted. In 2016, the FASB issued amendments to clarify the implementation guidance related to principal versus agent considerations, identifying performance obligations and the accounting for licenses of intellectual property. The new standard is required to be applied retrospectively to each prior reporting period or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application. The Company has not yet selected a transition method and is currently evaluating the standard to determine the impact of adoption on the Company’s consolidated financial statements.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities are excluded from the calculation of weighted average dilutive common shares for the following periods because their inclusion would have been anti-dilutive: As of September 30, 2016 2015 Stock options 7,338,621 6,300,359 Warrants 3,365,407 3,372,550 Non-vested restricted stock 1,473,217 737,902 Total 12,177,245 10,410,811

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2016
Business Acquisition, Pro Forma Information [Table Text Block]	The unaudited pro forma results of operations for the nine months ended September 30, 2015 are as follows (in thousands, except per share amounts): Nine Months Ended Revenues $ 12,324 Net loss $ (27,382) Net loss per share $ (1.17)

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Gain Loss on Disposal of Discontinued Operations [Table Text Block]	During the nine months ended September 30, 2016, the Company recorded a gain of approximately $ 3.3 0 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311
Disposal Groups, Including Discontinued Operations [Table Text Block]	Summarized operating results of discontinued operations for the three months ended September 30, 2015 and nine months ended September 30, 2016 are presented in the following table (in thousands). There were no operating results related to the sale of this asset during the three months ended September 30, 2016. Three Months Ended Ended September 30, Nine Months Ended Ended September 30, 2015 2016 2015 Revenue, net of returns, allowances and discounts $ 828 $ 1,709 $ 2,029 Cost of revenues 225 536 583 Gross profit 603 1,173 1,446 Selling, general and administrative 224 323 647 Income from discontinued operations, net of tax $ 379 $ 850 $ 799 Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands): September 30, December 31, 2016 2015 Accounts receivable, net $ 28 $ 457 Inventory, net - 858 Total current assets 28 1,315 Intangible assets, net - 227 Total assets 28 1,542 Accounts payable - 44 Accrued expenses and other current liabilities - 59 Total current liabilities $ - $ 103

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following (in thousands): September 30, December 31, 2016 2015 Raw materials $ 162 $ 241 Work in process 296 228 Finished goods 2,773 1,865 Less: Inventory reserve for excess and slow moving inventory (5) (59) Total $ 3,226 $ 2,275

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities consist of the following (in thousands): September 30, December 31, 2016 2015 Salaries, benefits and incentive compensation $ 2,326 $ 2,118 Professional fees 726 671 Royalty fees 570 52 Deferred revenue 142 92 Other 183 138 Total accrued expenses and other current liabilities $ 3,947 $ 3,071

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Instruments [Abstract]
Schedule of Debt [Table Text Block]	Debt consists of the following (in thousands): September 30, December 31, 2016 2015 Long-term debt $ 13,752 $ 15,500 Unamortized debt issuance and discount costs (2,416) (3,374) Total $ 11,336 $ 12,126

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Risk free interest rate 1.15%-1.44 % 0.32%-2.07 % 0.46%-2.06 % 0.26%-2.11 % Expected term (years) 5.50-6.50 0.76-6.50 0.53-6.50 0.76-6.50 Expected volatility 89.95 % 93.70 % 89.95 % 97.37 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the nine months ended September 30, 2016 is presented below: Number of Weighted Weighted Intrinsic Value Outstanding, December 31, 2015 6,230,549 $ 6.26 - $ - Granted 1,639,000 1.05 Exercised - - Forfeited (530,928) 3.83 Outstanding, September 30, 2016 7,338,621 $ 5.28 7.3 $ - Exerciseable, September 30, 2016 4,146,376 $ 6.14 6.4 $ -

Concentration of Risk (Tables)

Concentration of Risk (Tables)	9 Months Ended
	Sep. 30, 2016
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Revenue for the nine months ended September 30, 2016 and 2015 from the Company’s largest customer, a contract manufacturing customer, was as follows: % of Total Revenue Accounts Receivable Customer 2016 2015 September 30, 2016 A 9 % 11 % 3 %

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): Nine Months Ended September 30, 2016 2015 Warrant Liabilities Beginning balance $ 861 $ 304 Change in fair value of warrant liability (797) (1,388) Value of warrants issued - 2,683 Value of warrants exercised - (31) Ending balance $ 64 $ 1,568 Nine Months Ended September 30, 2016 2015 Contingent Consideration Beginning balance $ 17,028 $ 2,932 Initial fair value of contingent consideration - 15,570 Payments of contingent consideration (5,147) - Change in fair value of contingent consideration (8,634) 957 Ending balance $ 3,247 $ 19,459
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows (in thousands): September 30, 2016 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 64 Contingent consideration - - 3,247 Total liabilities $ - $ - $ 3,311 December 31, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 861 Contingent consideration - - 17,028 Total liabilities $ - $ - $ 17,889

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Net Income (Loss) Attributable to Parent, Total		$ (8,588)	$ (7,132)	$ (11,098)	$ (21,784)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total				(14,034)	(17,162)
Retained Earnings (Accumulated Deficit), Total		(107,158)		(107,158)		$ (107,158)	$ (96,060)
Cash and Cash Equivalents, at Carrying Value, Total		10,701	30,732	10,701	30,732	10,701	26,080	$ 16,771
Revenues, Total		4,874	$ 4,185	13,298	$ 8,234	22,250
Intangible Assets, Net (Including Goodwill)		52,000		52,000		52,000
Long-term Debt, Gross		13,752		13,752		13,752	$ 15,500
Senior Secured Debt [Member]
Long-term Debt, Gross		$ 13,800		$ 13,800		$ 13,800
Subsequent Event [Member]
Proceeds from Issuance of Common Stock And Debt	$ 45,000
Subsequent Event [Member] | Soluble Systems, LLC [Member]
Business Combination, Consideration Transferred, Total	$ 26,200

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,177,245	10,410,811
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,338,621	6,300,359
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,365,407	3,372,550
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,473,217	737,902

Acquisitions (Details)

Acquisitions (Details) - Acquisition of Celleration, Inc [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / shares
Business Acquisition [Line Items]
Revenues	$ 12,324
Net loss	$ (27,382)
Net loss per share | $ / shares	$ (1.17)

Acquisitions (Details Textual)

Acquisitions (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2016	May 29, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Revenues, Total			$ 4,874,000	$ 4,185,000	$ 13,298,000	$ 8,234,000		$ 22,250,000
Working Capital		$ 300,000
Business Combination, Contingent Consideration, at Fair Value					0	15,570,000
Payments to Acquire Businesses, Gross					2,573,000	0
Business Combination, Contingent Consideration, Liability, Noncurrent			1,848,000		1,848,000			1,848,000	$ 14,455,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			97,000	$ 585,000	(8,634,000)	$ 957,000
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Due To Accretion					406,000
Continget Consideration Installment Two [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent			$ 2,800,000		2,800,000			$ 2,800,000
MIST Therapy [Member]
Business Acquisition [Line Items]
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets									3.5
MIST Therapy [Member] | Scenario, Forecast [Member]
Business Acquisition [Line Items]
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets							3.5
2015 MIST Therapy
Business Acquisition [Line Items]
Revenues, Total					10,200,000
2014 MIST Therapy
Business Acquisition [Line Items]
Revenues, Total					$ 8,700,000
Acquisition of Celleration, Inc [Member]
Business Acquisition [Line Items]
Business Acquisition Initial Cash Payment		15,500,000
Business Combination, Contingent Consideration, at Fair Value		15,600,000
Business Combination, Consideration Transferred, Total		$ 46,300,000
Acquisition of Celleration, Inc [Member] | Installment One [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	986,000
Payments to Acquire Businesses, Gross	$ 2,600,000
Fair Value Inputs, Discount Rate					12.50%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,600,000
Acquisition of Celleration, Inc [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Acquisitions		3,168,229

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Proceeds from sale
Consideration for inventory			$ 603
Consideration for intangible assets			3,500
Total Consideration			4,103
Less: Net book value of assets sold to BSN
Inventory, net	$ (603)		(603)
Intangibles, net	(189)		(189)
Total net book value of assets	(792)		(792)
Gain on sale of assets	$ 0	$ 0	$ 3,311	$ 0

Discontinued Operations (Deta38

Discontinued Operations (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue, net of returns, allowances and discounts		$ 828	$ 1,709	$ 2,029
Cost of revenues		225	536	583
Gross profit		603	1,173	1,446
Selling, general and administrative		224	323	647
Income from discontinued operations, net of tax	$ 0	$ 379	$ 850	$ 799

Discontinued Operations (Deta39

Discontinued Operations (Details 2) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	$ 28	$ 457
Inventory, net	0	858
Total current assets	28	1,315
Intangible assets, net	0	227
Total assets	28	1,542
Accounts payable	0	44
Accrued expenses and other current liabilities	0	59
Total current liabilities	$ 0	$ 103

Discontinued Operations (Deta40

Discontinued Operations (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses and Interests in Affiliates			$ 3,500,000
Contractual Obligation	$ 900,000		900,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	0	$ 0	3,311,000	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	0	0	0	0
Sales Revenue, Services, Other	$ 100,000
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax			3,300,000
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of Intangible Assets		$ 19,000	$ 38,000	$ 57,000

Note Receivable (Details Textua

Note Receivable (Details Textual) - USD ($)	Sep. 30, 2016	Aug. 25, 2016
Interest Receivable	$ 3,000
Bridge Loan [Member]
Debt Instrument, Face Amount		$ 500,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 162	$ 241
Work in process	296	228
Finished goods	2,773	1,865
Less: Inventory reserve for excess and slow moving inventory	(5)	(59)
Total	$ 3,226	$ 2,275

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 2,326	$ 2,118
Professional fees	726	671
Royalty fees	570	52
Deferred revenue	142	92
Other	183	138
Total accrued expenses and other current liabilities	$ 3,947	$ 3,071

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt	$ 13,752	$ 15,500
Unamortized debt issuance and discount costs	(2,416)	(3,374)
Total	$ 11,336	$ 12,126

Debt (Details Textual)

Debt (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Dec. 31, 2015	May 29, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001			$ 0.001		$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.5138			$ 5.5138		$ 5.5138
Derivative Liability	$ 64,000	$ 1,568,000		$ 64,000	$ 1,568,000	$ 64,000	$ 861,000		$ 304,000
Amortization of Debt Discount (Premium)				$ 636,000	326,000
Warrant Expiration Period				five-year warrant
Common Stock Purchased By Warrants Issued				750,000
Proceeds from Divestiture of Businesses and Interests in Affiliates				$ 3,500,000
Exit fee payment, Credit Agreement Description				The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000, which was amended in conjunction with the extinguishment of debt described below from the greater of 1% of the outstanding principal balance immediately prior to the final payment or $100,000.
Gain (Loss) on Extinguishment of Debt	(373,000)	0		$ (373,000)	0
Revenues, Total	4,874,000	4,185,000		13,298,000	8,234,000	22,250,000
Long-term Debt, Gross	13,752,000			13,752,000		13,752,000	15,500,000
Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability	64,000			64,000		64,000	$ 861,000
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability	2,700,000			2,700,000		2,700,000
Interest Expense [Member]
Debt Instrument [Line Items]
Amortization of Financing Costs	64,000	72,000		209,000	98,000
Amortization of Debt Discount (Premium)	143,000	$ 168,000		427,000	$ 227,000
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount								$ 15,500,000
Debt Issuance Costs1				$ 1,300,000
Amortization of Debt Discount (Premium)	226,000
Debt Instrument, Interest Rate Terms				accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%
Debt Instrument, Term				4 years
Debt Instrument, Payment Terms				is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date
Debt Instrument, Interest Rate During Period				10.75%
Payments for Prepayment Penalties			$ 52,000
Proceeds from Divestiture of Businesses and Interests in Affiliates			1,800,000
Repayments of Debt			$ 1,700,000
Gain (Loss) on Extinguishment of Debt	373,000
Prepayment Penalty On Early Extinguishment Of Debt	52,000
Write off of Deferred Debt Issuance Cost	95,000
Long-term Debt, Gross	$ 13,800,000			$ 13,800,000		$ 13,800,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jul. 15, 2011	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Commitments And Contingencies [Line Items]
Accounts Payable, Current		$ 2,590,000		$ 2,590,000		$ 2,594,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months		577,000		577,000
Operating Leases, Future Minimum Payments, Due in Two Years		78,000		78,000
Operating Leases, Future Minimum Payments, Due in Three Years		80,000		80,000
Operating Leases, Future Minimum Payments, Due in Four Years		82,000		82,000
Operating Leases, Future Minimum Payments, Due in Five Years		84,000		84,000
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year		27,000		27,000
AIQA Cedar Inc [Member]
Commitments And Contingencies [Line Items]
Accounts Payable, Current		449,000		449,000		$ 497,000
Alliqua Biomedical Subsidiary [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months		600,000		600,000
Royalty Expense		150,000	$ 125,000	450,000	$ 375,000
Human Longevity, Inc [Member]
Commitments And Contingencies [Line Items]
Revenue Recognition, Milestone Method, Milestone Expenses		1,000,000		1,000,000
Human Longevity, Inc [Member] | First Commercial Sale [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months		500,000		500,000
Human Longevity, Inc [Member] | Second Commercial Sale [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months		$ 500,000		$ 500,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage	9.75%

Stockholders' Equity (Details)

Stockholders' Equity (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	89.95%	93.70%	89.95%	97.37%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.15%	0.32%	0.46%	0.26%
Expected term (years)	5 years 6 months	9 months 4 days	6 months 11 days	9 months 4 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.44%	2.07%	2.06%	2.11%
Expected term (years)	6 years 6 months	6 years 6 months	6 years 6 months	6 years 6 months

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - Employee Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	6,230,549
Number of Options, Granted (in shares)	1,639,000
Number of Options, Exercised (in shares)	0
Number of Options, Forfeited (in shares)	(530,928)
Number of Options, Outstanding at End of the period (in shares)	7,338,621	6,230,549
Number of Options, Exercisable, September 30, 2016 (in shares)	4,146,376
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$ 6.26
Weighted Average Exercise Price, Granted (in dollars per share)	1.05
Weighted Average Exercise Price, Exercised (in dollars per share)	0
Weighted Average Exercise Price, Forfeited (in dollars per share)	3.83
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	5.28	$ 6.26
Weighted Average Exercise Price, Exercisable September 30, 2016 (in dollars per share)	$ 6.14
Weighted Average Remaining Life In Years, Outstanding, September 30, 2016 (Years)	7 years 3 months 18 days	0 years
Weighted Average Remaining Life In Years, Exercisable, Exercisable, September 30, 2016 (Years)	6 years 4 months 24 days
Intrinsic Value, Outstanding, September 30, 2016	$ 0	$ 0
Intrinsic Value, Exercisable, September 30, 2016	$ 0

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	May 11, 2016	Feb. 09, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	May 06, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 1,200,000	$ 2,300,000	$ 4,300,000	$ 6,600,000
Common Stock, Shares Authorized			95,000,000		95,000,000		45,714,286	95,000,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 0.76	$ 3.78	$ 0.76	$ 4.27
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 5,000	$ 91,000	$ 134,000	$ 273,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			1,200,000	$ 2,200,000	4,100,000	$ 6,300,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total			$ 4,700,000		$ 4,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					1 year 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	700,000	324,561
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value	$ 602,000	$ 474,000

Related Party (Details Textual)

Related Party (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 100,000	$ 358,000
Accounts Payable, Related Parties	$ 30,000	$ 30,000	$ 5,000

Concentration of Risk (Details)

Concentration of Risk (Details) - Customer A [Member]	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	9.00%	11.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	3.00%

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 861	$ 304
Initial fair value of contingent consideration	0	15,570
Value of warrants issued	0	2,683
Value of warrants exercised	0	(31)
Change in fair value of warrant liability	(797)	(1,388)
Ending balance	64	1,568
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	17,028	2,932
Initial fair value of contingent consideration	0	15,570
Payments of contingent consideration	(5,147)	0
Change in fair value of warrant liability	(8,634)	957
Ending balance	$ 3,247	$ 19,459

Fair Value Measurement (Detai53

Fair Value Measurement (Details 1) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Liabilities:
Warrant liabilities	$ 64	$ 861	$ 1,568	$ 304
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	64	861
Contingent consideration	3,247	17,028
Total liabilities	$ 3,311	$ 17,889

Fair Value Measurement (Detai54

Fair Value Measurement (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)	$ 135,000	$ 1,500,000	$ 797,000	$ 1,400,000
Derivative Liability	64,000	$ 1,568,000	64,000	$ 1,568,000	$ 861,000	$ 304,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	64,000		$ 64,000		$ 861,000
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Dividend Rate			0.00%
Warrants To Purchase Common Stock			816,287
Derivative Liability	$ 64,000		$ 64,000
Fair Value, Inputs, Level 3 [Member] | Maximum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate			69.55%
Fair Value Assumptions, Risk Free Interest Rate			1.01%
Fair Value Assumptions, Expected Term			3 years 7 months 28 days
Fair Value, Inputs, Level 3 [Member] | Minimum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate			66.95%
Fair Value Assumptions, Risk Free Interest Rate			0.59%
Fair Value Assumptions, Expected Term			1 year 1 month 10 days

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Taxes [Line Items]
Income tax (expense) benefit		$ (3)	$ (129)	$ (9)	$ 1,308
Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Income Tax Expense	$ 1,400

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	1 Months Ended
	Oct. 31, 2016	Oct. 05, 2016	Aug. 25, 2016
Bridge Loan [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount			$ 500,000
Subsequent Event [Member] | Soluble Systems, LLC [Member]
Subsequent Event [Line Items]
Proceeds from Issuance Of Secured Debt or Equity Financing or Combination of Secured Debt And Equity Financing	$ 45,000,000
Cash Advance		$ 500,000
Subsequent Event [Member] | Soluble Systems, LLC [Member] | Bridge Loan [Member] | Maximum [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount		1,000,000
Subsequent Event [Member] | Soluble Systems, LLC [Member] | Bridge Loan [Member] | Minimum [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount		$ 500,000
Subsequent Event [Member] | Soluble Systems, LLC [Member] | ALLIQUA BIOMEDICAL, INC [Member]
Subsequent Event [Line Items]
Receivables, Net, Current	$ 26,200,000